ArticleCurrent therapeutic research, clinical and experimental2022

Feasibility study of Bismuth Subsalicylate (BSS) as an addition to standard of care for COVID-19 therapy.

Mary Beth Yacyshyn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.